Business Context and Reporting Period
Company: Electromed, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2011
Business Overview: Electromed develops, manufactures, and markets airway clearance products utilizing High Frequency Chest Wall Oscillation (HFCWO) therapy, primarily the SmartVest® system. The company serves home health care and institutional markets in the U.S. and internationally. The company is classified as a smaller reporting company.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2011 | Nine Months Ended Mar 31, 2011 |
|---|---|---|
| Net Revenues | $5,198,828 | $14,049,803 |
| Gross Profit | $3,703,319 (71.2% margin) | $10,177,238 (72.4% margin) |
| Operating Income | $671,506 | $1,462,300 |
| Net Income | $487,429 | $891,371 |
| Cash and Cash Equivalents | $3,952,032 (as of Mar 31, 2011) | |
| Total Debt (Current + Long-term) | $3,302,000 (as of Mar 31, 2011) | |
| Unused Credit Availability | $2,232,000 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 22.9% for the three months and 31.6% for the nine months ended March 31, 2011, compared to the prior year. This was driven by a 25.8% increase in Home Care revenue and a 55.5% increase in Government/Institutional revenue.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 36.3% (quarterly) and 41.3% (nine-month) due to a significant expansion of the sales force (from 15 to 23 FTEs quarterly) and increased marketing/travel costs. R&D expenses increased 40.2% (quarterly) and 54.8% (nine-month).
- Profitability: While net income increased in absolute dollars ($487k vs $475k quarterly), net income as a percentage of revenue decreased from 11.2% to 9.4% due to the strategic investment in sales and marketing infrastructure.
- Cash Flow: Operating cash flow turned negative, using $1.28 million for the nine months ended March 31, 2011, compared to a positive $1.09 million in the prior year. This was primarily due to a $2.66 million increase in accounts receivable resulting from sales growth and collection lags.
- Capital Structure: The company completed an IPO in August 2010, raising approximately $5.95 million in net proceeds. This capital was used to pay down debt and fund operations.
Guidance, Outlook, and Risks
- Outlook: Management believes the expansion of the sales force, support personnel, and R&D efforts provides a foundation for increased market share. They anticipate R&D expenses to remain at approximately 5% or greater of revenue.
- Liquidity: Management asserts that current cash, IPO proceeds, and available borrowings under the $3.5 million revolving credit facility are sufficient to meet liquidity needs for at least the next 12 months.
- Legal Contingencies: A trademark infringement lawsuit regarding the "SmartVest" mark brought by Hill-Rom was settled on September 30, 2010. The terms are confidential, but the company retains the right to use the mark. Approximately $1.16 million in legal defense costs were capitalized.
- Risks: Key risks include the competitive nature of the market, changes in Medicare/Medicaid reimbursement policies, the ability to recruit and retain sales staff, and the impact of tight credit markets on financing.
Investor Verification Checklist
- Accounts Receivable Aging: Verify the collectability of the $9.2 million in accounts receivable, which increased by $2.66 million in the nine-month period, contributing to negative operating cash flow.
- Sales Force Efficiency: Monitor whether the 50% increase in sales staff FTEs continues to yield proportional revenue growth in future quarters to justify the increased SG&A burden.
- Debt Covenants: Review the financial covenants (fixed charge and cash flow coverage ratios) associated with the U.S. Bank credit facility to ensure compliance given the shift to negative operating cash flow.
- Reimbursement Trends: Assess the stability of reimbursement rates from third-party payors, as the business model relies heavily on home care and institutional reimbursement.